Compare ATLO & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATLO | MDWD |
|---|---|---|
| Founded | 1903 | 2000 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 205.2M | 224.6M |
| IPO Year | 2001 | 2013 |
| Metric | ATLO | MDWD |
|---|---|---|
| Price | $27.35 | $17.63 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $36.00 |
| AVG Volume (30 Days) | 36.1K | ★ 75.3K |
| Earning Date | 04-24-2026 | 01-01-0001 |
| Dividend Yield | ★ 2.93% | N/A |
| EPS Growth | ★ 8.03 | N/A |
| EPS | ★ 0.38 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $6.97 |
| Revenue Next Year | N/A | $23.59 |
| P/E Ratio | $71.97 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.09 | $14.14 |
| 52 Week High | $28.35 | $22.51 |
| Indicator | ATLO | MDWD |
|---|---|---|
| Relative Strength Index (RSI) | 58.07 | 50.59 |
| Support Level | $19.47 | $16.71 |
| Resistance Level | $28.33 | $18.58 |
| Average True Range (ATR) | 0.65 | 0.56 |
| MACD | -0.22 | 0.01 |
| Stochastic Oscillator | 47.22 | 53.30 |
Ames National Corporation is a United States-based bank holding company. It provides short-term and medium-term commercial, multi-family, and agricultural real estate loans, residential real estate loans, agricultural and business operating loans and lines of credit, equipment loans, vehicle loans, personal loans and lines of credit, home improvement loans and origination of mortgage loans for sale into the secondary market. The Banks also offer a variety of checking, savings and time deposits, cash management services, merchant credit card processing, safe deposit boxes, wire transfers, direct deposit and automated/video teller machine access. The banking segment generates revenues through personal, business, agricultural and commercial lending, and Others.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.